organization · Reporting owner

Forbion Growth Management B.V.

Disclosed activity across 3 companies

Tapewire entity: 84624
SEC CIK: 0001918318

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Forbion European Acquisition Corp.FRBNU · Entity 108709	Director · 10% owner	October 30, 2023	October 31, 2023
enGene Therapeutics Inc.ENGN · Entity 6638	10% owner	October 30, 2024	November 01, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Forbion European Acquisition Corp.

Report date October 30, 2023 · Filed October 31, 2023

Jointly reported with Forbion Growth Sponsor FEAC I B.V., Forbion Growth Opportunities Fund I Cooperatief U.A.

Security / award	Ownership account	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	Reported balance After 2023-10-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-30 · Disposition to issuer · Disposed 1,373,496 · Balance 0 F1: On October 31, 2023, in connection with the consummation of the Issuer's initial business combination, Class A Ordinary Shares were exchanged, on a one-for-one basis, for Class A common shares ("New enGene Shares") of enGene Holdings, Inc., a corporation incorporated under the laws of Canada ("New enGene"), which will be the parent company of the combined operating business following the consummation of initial business combination, as described in more detail in that certain Business Combination Agreement between the Issuer, enGene Inc. and enGene Holdings Inc., dated May 16, 2023 (the "Business Combination Agreement"). F2: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.
Class A Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnotes	Reported balance After 2023-10-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-10-30 · Disposition to issuer · Disposed 2,000,000 · Balance 0 F1: On October 31, 2023, in connection with the consummation of the Issuer's initial business combination, Class A Ordinary Shares were exchanged, on a one-for-one basis, for Class A common shares ("New enGene Shares") of enGene Holdings, Inc., a corporation incorporated under the laws of Canada ("New enGene"), which will be the parent company of the combined operating business following the consummation of initial business combination, as described in more detail in that certain Business Combination Agreement between the Issuer, enGene Inc. and enGene Holdings Inc., dated May 16, 2023 (the "Business Combination Agreement"). F3: Reflects shares held by Forbion Growth Opportunities Fund I cooperatief U.A. ("Forbion Cooperatief"). F4: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	IndirectSee Footnotes	Reported balance After 2023-10-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-30 · Disposition to issuer · Disposed 731,619 · Balance 0 F9: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F8: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F2: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	IndirectSee Footnotes	Reported balance After 2023-10-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-10-30 · Disposition to issuer · Disposed 666,666 · Balance 0 F9: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F8: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F3: Reflects shares held by Forbion Growth Opportunities Fund I cooperatief U.A. ("Forbion Cooperatief"). F4: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On October 31, 2023, in connection with the consummation of the Issuer's initial business combination, Class A Ordinary Shares were exchanged, on a one-for-one basis, for Class A common shares ("New enGene Shares") of enGene Holdings, Inc., a corporation incorporated under the laws of Canada ("New enGene"), which will be the parent company of the combined operating business following the consummation of initial business combination, as described in more detail in that certain Business Combination Agreement between the Issuer, enGene Inc. and enGene Holdings Inc., dated May 16, 2023 (the "Business Combination Agreement").

F2: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board.

F3: Reflects shares held by Forbion Growth Opportunities Fund I cooperatief U.A. ("Forbion Cooperatief").

F4: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein.

F5: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor.

F6: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares.

F7: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein.

F8: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering.

F9: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement

enGene Therapeutics Inc.

Report date October 30, 2024 · Filed November 01, 2024

Jointly reported with Forbion Growth Opportunities Fund I Cooperatief U.A.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	3,032,430	Reported balance After 2024-10-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-10-30 · Purchase · Acquired 561,797 · Balance 3,032,430 F1: On October 30, 2024, Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief") acquired 561,797 Common Shares in a private placement by the Issuer pursuant to the terms of a Subscription Agreement dated October 24, 2024. F2: Shares held by Forbion Cooperatief. Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any.
Common SharesSEC Table I · non-derivative	IndirectBy Forbion Growth Sponsor FEAC I B.V.	3,765,932	Reported balance Holding disclosure · report date 2024-10-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,765,932 F3: Shares held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is wholly owned by Forbion Cooperatief, and is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On October 30, 2024, Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief") acquired 561,797 Common Shares in a private placement by the Issuer pursuant to the terms of a Subscription Agreement dated October 24, 2024.

F2: Shares held by Forbion Cooperatief. Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any.

F3: Shares held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is wholly owned by Forbion Cooperatief, and is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NewAmsterdam Pharma Co N.V.

Report date December 30, 2024 · Filed January 02, 2025

Jointly reported with ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., Forbion IV Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A.

Section 16 reporting ended · disclosed 2025-01-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectSee footnote	10,656,172	Reported balance After 2024-12-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-12-30 · Sale · Disposed 29,846 · Balance 10,656,172 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2: Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10. F3: (Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV. F4: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024.

F2: Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10.

F3: (Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV.

F4: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 30, 2024 Filed Jan 2, 2025 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	29,846	$25.54	$762,174.32	Disclosure SEC source: 0000950170-25-000445 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,656,172 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10. F3 · shares: (Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV. F2 · price: Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10. F3 · price: (Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	41,472	$25.95	$1,076,289.64	Disclosure SEC source: 0000950170-24-141146 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,686,018 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 18,215 shares sold on behalf of Forbion Growth I and 23,257 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.75 to $26.325. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,686,018 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,033,845 are held by PoolCo and are allocated to ForGrowth, of which 4,040,820 shares are beneficially owned by Forbion Growth I and 5,993,025 shares are beneficially owned by Forbion IV. F5 · price: Represents 18,215 shares sold on behalf of Forbion Growth I and 23,257 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.75 to $26.325. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,686,018 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,033,845 are held by PoolCo and are allocated to ForGrowth, of which 4,040,820 shares are beneficially owned by Forbion Growth I and 5,993,025 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 26, 2024 Filed Dec 30, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	33,438	$26.01	$869,628.75	Disclosure SEC source: 0000950170-24-141146 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,727,490 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 14,686 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 18,752 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.705 to $26.25. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · shares: (Continued from footnote 2) Following the reported transaction, of the 10,727,490 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,075,317 are held by PoolCo and are allocated to ForGrowth, of which 4,059,035 shares are beneficially owned by Forbion Growth I and 6,016,282 shares are beneficially owned by Forbion IV. F2 · price: Represents 14,686 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 18,752 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.705 to $26.25. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · price: (Continued from footnote 2) Following the reported transaction, of the 10,727,490 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,075,317 are held by PoolCo and are allocated to ForGrowth, of which 4,059,035 shares are beneficially owned by Forbion Growth I and 6,016,282 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 24, 2024 Filed Dec 26, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	16,164	$25.66	$414,831.28	Disclosure SEC source: 0000950170-24-140408 · ownership.xml · nonDerivative · entry 4 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,760,928 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F7 · shares: Represents 7,099 shares sold on behalf of Forbion Growth I and 9,065 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.23 to $26.00. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,760,928 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,108,755 are held by PoolCo and are allocated to ForGrowth, of which 4,073,721 shares are beneficially owned by Forbion Growth I and 6,035,034 shares are beneficially owned by Forbion IV. F7 · price: Represents 7,099 shares sold on behalf of Forbion Growth I and 9,065 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.23 to $26.00. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,760,928 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,108,755 are held by PoolCo and are allocated to ForGrowth, of which 4,073,721 shares are beneficially owned by Forbion Growth I and 6,035,034 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 23, 2024 Filed Dec 26, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	25,132	$25.49	$640,624.73	Disclosure SEC source: 0000950170-24-140408 · ownership.xml · nonDerivative · entry 3 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,777,092 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F6 · shares: Represents 11,038 shares sold on behalf of Forbion Growth I and 14,094 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.835. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,777,092 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,124,919 are held by PoolCo and are allocated to ForGrowth, of which 4,080,820 shares are beneficially owned by Forbion Growth I and 6,044,099 shares are beneficially owned by Forbion IV. F6 · price: Represents 11,038 shares sold on behalf of Forbion Growth I and 14,094 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.835. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,777,092 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,124,919 are held by PoolCo and are allocated to ForGrowth, of which 4,080,820 shares are beneficially owned by Forbion Growth I and 6,044,099 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 20, 2024 Filed Dec 26, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	5,629	$26.13	$147,071.13	Disclosure SEC source: 0000950170-24-140408 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,802,224 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 2,472 shares sold on behalf of Forbion Growth I and 3,157 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.02 to $26.205. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,802,224 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,150,051 are held by PoolCo and are allocated to ForGrowth, of which 4,091,858 shares are beneficially owned by Forbion Growth I and 6,058,193 shares are beneficially owned by Forbion IV. F5 · price: Represents 2,472 shares sold on behalf of Forbion Growth I and 3,157 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.02 to $26.205. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,802,224 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,150,051 are held by PoolCo and are allocated to ForGrowth, of which 4,091,858 shares are beneficially owned by Forbion Growth I and 6,058,193 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 20, 2024 Filed Dec 26, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	44,143	$25.53	$1,126,992.86	Disclosure SEC source: 0000950170-24-140408 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,807,853 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 19,388 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 24,755 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,807,853 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,155,680 are held by PoolCo and are allocated to ForGrowth, F3 · shares: (Continued from footnote 2) of which 4,094,330 shares are beneficially owned by Forbion Growth I and 6,061,350 shares are beneficially owned by Forbion IV. F2 · price: Represents 19,388 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 24,755 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,807,853 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,155,680 are held by PoolCo and are allocated to ForGrowth, F3 · price: (Continued from footnote 2) of which 4,094,330 shares are beneficially owned by Forbion Growth I and 6,061,350 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 19, 2024 Filed Dec 20, 2024 21:25 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	56,506	$25.45	$1,437,806.47	Disclosure SEC source: 0000950170-24-139069 · ownership.xml · nonDerivative · entry 3 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,851,996 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F6 · shares: Represents 24,817 shares sold on behalf of Forbion Growth I and 31,689 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.94. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,851,996 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,199,823 are held by PoolCo and are allocated to ForGrowth, of which 4,113,718 shares are beneficially owned by Forbion Growth I and 6,086,105 shares are beneficially owned by Forbion IV. F6 · price: Represents 24,817 shares sold on behalf of Forbion Growth I and 31,689 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.94. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,851,996 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,199,823 are held by PoolCo and are allocated to ForGrowth, of which 4,113,718 shares are beneficially owned by Forbion Growth I and 6,086,105 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 18, 2024 Filed Dec 20, 2024 21:25 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	46,210	$26.55	$1,226,857.02	Disclosure SEC source: 0000950170-24-139069 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,908,502 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 20,295 shares sold on behalf of Forbion Growth I and 25,915 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.165 to $26.88. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,908,502 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,256,329 are held by PoolCo and are allocated to ForGrowth, of which 4,138,535 shares are beneficially owned by Forbion Growth I and 6,117,794 shares are beneficially owned by Forbion IV. F5 · price: Represents 20,295 shares sold on behalf of Forbion Growth I and 25,915 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.165 to $26.88. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,908,502 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,256,329 are held by PoolCo and are allocated to ForGrowth, of which 4,138,535 shares are beneficially owned by Forbion Growth I and 6,117,794 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 18, 2024 Filed Dec 20, 2024 21:25 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	54,518	$25.72	$1,402,050.31	Disclosure SEC source: 0000950170-24-139069 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,954,712 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 23,944 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 30,574 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.165 to $26.155. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · shares: (Continued from footnote 2) Following the reported transaction, of the 10,954,712 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,302,539 are held by PoolCo and are allocated to ForGrowth, of which 4,158,830 shares are beneficially owned by Forbion Growth I and 6,143,709 shares are beneficially owned by Forbion IV. F2 · price: Represents 23,944 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 30,574 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.165 to $26.155. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · price: (Continued from footnote 2) Following the reported transaction, of the 10,954,712 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,302,539 are held by PoolCo and are allocated to ForGrowth, of which 4,158,830 shares are beneficially owned by Forbion Growth I and 6,143,709 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 17, 2024 Filed Dec 18, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	47,736	$26.45	$1,262,440.58	Disclosure SEC source: 0000950170-24-137893 · ownership.xml · nonDerivative · entry 3 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,009,230 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 20,966 shares sold on behalf of Forbion Growth I and 26,770 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $25.855. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,009,230 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,357,057 are held by PoolCo and are allocated to ForGrowth, of which 4,182,774 shares are beneficially owned by Forbion Growth I and 6,174,283 shares are beneficially owned by Forbion IV. F5 · price: Represents 20,966 shares sold on behalf of Forbion Growth I and 26,770 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $25.855. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,009,230 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,357,057 are held by PoolCo and are allocated to ForGrowth, of which 4,182,774 shares are beneficially owned by Forbion Growth I and 6,174,283 shares are beneficially owned by Forbion IV. F3 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 17, 2024 Filed Dec 18, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	66,648	$25.60	$1,706,315.43	Disclosure SEC source: 0000950170-24-137893 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,056,966 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F4 · shares: Represents 29,272 shares sold on behalf of Forbion Growth I and 37,376 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,056,966 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,404,793 are held by PoolCo and are allocated to ForGrowth, of which 4,203,740 shares are beneficially owned by Forbion Growth I and 6,201,053 shares are beneficially owned by Forbion IV. F4 · price: Represents 29,272 shares sold on behalf of Forbion Growth I and 37,376 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,056,966 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,404,793 are held by PoolCo and are allocated to ForGrowth, of which 4,203,740 shares are beneficially owned by Forbion Growth I and 6,201,053 shares are beneficially owned by Forbion IV. F3 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 16, 2024 Filed Dec 18, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	1,096	$25.00	$27,400.00	Disclosure SEC source: 0000950170-24-137893 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,123,614 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 481 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 615 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). Following the reported transaction, of the 11,123,614 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,471,441 are held by PoolCo and are allocated to ForGrowth, of which 4,233,012 shares are beneficially owned by Forbion Growth I and 6,238,429 shares are beneficially owned by Forbion IV. F3 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 13, 2024 Filed Dec 16, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	25,751	$25.01	$644,047.96	Disclosure SEC source: 0000950170-24-136642 · ownership.xml · nonDerivative · entry 3 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,124,710 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F6 · shares: Represents 11,310 shares sold on behalf of Forbion Growth I and 14,441 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.13. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,124,710 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,472,537 are held by PoolCo and are allocated to ForGrowth, of which 4,233,493 shares are beneficially owned by Forbion Growth I and 6,239,044 shares are beneficially owned by Forbion IV. F6 · price: Represents 11,310 shares sold on behalf of Forbion Growth I and 14,441 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.13. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,124,710 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,472,537 are held by PoolCo and are allocated to ForGrowth, of which 4,233,493 shares are beneficially owned by Forbion Growth I and 6,239,044 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 12, 2024 Filed Dec 16, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	25,963	$26.18	$679,615.28	Disclosure SEC source: 0000950170-24-136642 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,150,461 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 11,403 shares sold on behalf of Forbion Growth I and 14,560 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.405. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,150,461 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,498,288 are held by PoolCo and are allocated to ForGrowth, of which 4,244,803 shares are beneficially owned by Forbion Growth I and 6,253,485 shares are beneficially owned by Forbion IV. F5 · price: Represents 11,403 shares sold on behalf of Forbion Growth I and 14,560 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.405. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,150,461 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,498,288 are held by PoolCo and are allocated to ForGrowth, of which 4,244,803 shares are beneficially owned by Forbion Growth I and 6,253,485 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 12, 2024 Filed Dec 16, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	140,048	$25.25	$3,536,212.00	Disclosure SEC source: 0000950170-24-136642 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,176,424 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 61,509 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 78,539 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,176,424 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,524,251 are held by PoolCo and are allocated to ForGrowth, F3 · shares: (Continued from footnote 2) of which 4,256,206 shares are beneficially owned by Forbion Growth I and 6,268,045 shares are beneficially owned by Forbion IV. F2 · price: Represents 61,509 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 78,539 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,176,424 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,524,251 are held by PoolCo and are allocated to ForGrowth, F3 · price: (Continued from footnote 2) of which 4,256,206 shares are beneficially owned by Forbion Growth I and 6,268,045 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	4,894	$27.11	$132,671.45	Disclosure SEC source: 0000950170-24-135796 · ownership.xml · nonDerivative · entry 5 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,316,472 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F8 · shares: Represents 2,149 shares sold on behalf of Forbion Growth I and 2,745 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.09 to $27.21. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,316,472 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,664,299 are held by PoolCo and are allocated to ForGrowth, of which 4,317,715 shares are beneficially owned by Forbion Growth I and 6,346,584 shares are beneficially owned by Forbion IV. F8 · price: Represents 2,149 shares sold on behalf of Forbion Growth I and 2,745 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.09 to $27.21. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,316,472 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,664,299 are held by PoolCo and are allocated to ForGrowth, of which 4,317,715 shares are beneficially owned by Forbion Growth I and 6,346,584 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	18,583	$26.41	$490,684.12	Disclosure SEC source: 0000950170-24-135796 · ownership.xml · nonDerivative · entry 4 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,321,366 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F7 · shares: Represents 8,162 shares sold on behalf of Forbion Growth I and 10,421 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.80. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,321,366 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,669,193 are held by PoolCo and are allocated to ForGrowth, of which 4,319,864 shares are beneficially owned by Forbion Growth I and 6,349,329 shares are beneficially owned by Forbion IV. F7 · price: Represents 8,162 shares sold on behalf of Forbion Growth I and 10,421 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.80. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,321,366 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,669,193 are held by PoolCo and are allocated to ForGrowth, of which 4,319,864 shares are beneficially owned by Forbion Growth I and 6,349,329 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 11, 2024 Filed Dec 12, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	130,561	$25.26	$3,298,453.94	Disclosure SEC source: 0000950170-24-135796 · ownership.xml · nonDerivative · entry 3 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,339,949 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F6 · shares: Represents 57,342 shares sold on behalf of Forbion Growth I and 73,219 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,339,949 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,687,776 are held by PoolCo and are allocated to ForGrowth, of which 4,328,026 shares are beneficially owned by Forbion Growth I and 6,359,750 shares are beneficially owned by Forbion IV. F6 · price: Represents 57,342 shares sold on behalf of Forbion Growth I and 73,219 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,339,949 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,687,776 are held by PoolCo and are allocated to ForGrowth, of which 4,328,026 shares are beneficially owned by Forbion Growth I and 6,359,750 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 10, 2024 Filed Dec 12, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	48,511	$26.15	$1,268,606.31	Disclosure SEC source: 0000950170-24-135796 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,470,510 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 21,306 shares sold on behalf of Forbion Growth I and 27,205 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.33. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,470,510 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,818,337 are held by PoolCo and are allocated to ForGrowth, of which 4,385,368 shares are beneficially owned by Forbion Growth I and 6,432,969 shares are beneficially owned by Forbion IV. F5 · price: Represents 21,306 shares sold on behalf of Forbion Growth I and 27,205 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.33. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,470,510 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,818,337 are held by PoolCo and are allocated to ForGrowth, of which 4,385,368 shares are beneficially owned by Forbion Growth I and 6,432,969 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
December 10, 2024 Filed Dec 12, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	259,739	$25.22	$6,550,202.00	Disclosure SEC source: 0000950170-24-135796 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,519,021 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 114,077 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 145,662 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,519,021 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,866,848 are held by PoolCo and are allocated to ForGrowth, F3 · shares: (Continued from footnote 2) of which 4,406,674 shares are beneficially owned by Forbion Growth I and 6,460,174 shares are beneficially owned by Forbion IV. F2 · price: Represents 114,077 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 145,662 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,519,021 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,866,848 are held by PoolCo and are allocated to ForGrowth, F3 · price: (Continued from footnote 2) of which 4,406,674 shares are beneficially owned by Forbion Growth I and 6,460,174 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
November 18, 2024 Filed Nov 19, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	33,273	$25.08	$834,440.26	Disclosure SEC source: 0000950170-24-128607 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,778,760 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 14,614 shares sold on behalf of Forbion Growth I and 18,659 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.28. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,778,760 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,126,587 are held by PoolCo and are allocated to ForGrowth, of which in 4,520,751 shares are beneficially owned by Forbion Growth I and 6,605,836 shares are beneficially owned by Forbion IV. F5 · price: Represents 14,614 shares sold on behalf of Forbion Growth I and 18,659 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.28. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,778,760 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,126,587 are held by PoolCo and are allocated to ForGrowth, of which in 4,520,751 shares are beneficially owned by Forbion Growth I and 6,605,836 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:15 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	8,530	$25.02	$213,435.95	Disclosure SEC source: 0000950170-24-128607 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,812,033 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 3,746 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 4,784 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.115. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · shares: (Continued from footnote 2) Following the reported transaction, of the 11,812,033 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,159,860 are held by PoolCo and are allocated to ForGrowth, of which in 4,535,365 shares are beneficially owned by Forbion Growth I and 6,624,495 shares are beneficially owned by Forbion IV. F2 · price: Represents 3,746 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 4,784 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.115. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · price: (Continued from footnote 2) Following the reported transaction, of the 11,812,033 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,159,860 are held by PoolCo and are allocated to ForGrowth, of which in 4,535,365 shares are beneficially owned by Forbion Growth I and 6,624,495 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
November 14, 2024 Filed Nov 15, 2024 21:36 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	9,832	$25.01	$245,856.04	Disclosure SEC source: 0000950170-24-127643 · ownership.xml · nonDerivative · entry 2 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,820,563 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F5 · shares: Represents 4,318 shares sold on behalf of Forbion Growth I and 5,514 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.10. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,820,563 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,168,390 are held by PoolCo and are allocated to ForGrowth NAP B.V, of which 4,539,111 shares are beneficially owned by Forbion Growth I and 6,629,279 shares are beneficially owned by Forbion IV. F5 · price: Represents 4,318 shares sold on behalf of Forbion Growth I and 5,514 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.10. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,820,563 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,168,390 are held by PoolCo and are allocated to ForGrowth NAP B.V, of which 4,539,111 shares are beneficially owned by Forbion Growth I and 6,629,279 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"), but does not exercise voting or dispositive power over the Ordinary Shares held by PoolCo on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
November 13, 2024 Filed Nov 15, 2024 21:36 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	1,066	$25.00	$26,654.58	Disclosure SEC source: 0000950170-24-127643 · ownership.xml · nonDerivative · entry 1 ForGrowth NAP B.V. · CIK 0002005407 · 10% owner Forbion Capital Fund IV Cooperatief U.A. · CIK 0001823747 · 10% owner Forbion IV Management B.V. · CIK 0002005384 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,830,395 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024. F2 · shares: Represents 468 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 598 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.06. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · shares: (Continued from footnote 2) Following the reported transaction, of the 11,830,395 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,178,222 are held by PoolCo and are allocated to ForGrowth NAP B.V., of which in 4,543,429 shares are beneficially owned by Forbion Growth I and 6,634,793 shares are beneficially owned by Forbion IV. F2 · price: Represents 468 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 598 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.06. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · price: (Continued from footnote 2) Following the reported transaction, of the 11,830,395 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 11,178,222 are held by PoolCo and are allocated to ForGrowth NAP B.V., of which in 4,543,429 shares are beneficially owned by Forbion Growth I and 6,634,793 shares are beneficially owned by Forbion IV. F4 · ownership.nature: ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"), but does not exercise voting or dispositive power over the Ordinary Shares held by PoolCo on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose. Read SEC document
October 30, 2024 Filed Nov 1, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	561,797	$8.90	$4,999,993.30	Disclosure SEC source: 0000950170-24-120079 · ownership.xml · nonDerivative · entry 1 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,032,430 F1 · kind: On October 30, 2024, Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief") acquired 561,797 Common Shares in a private placement by the Issuer pursuant to the terms of a Subscription Agreement dated October 24, 2024. F2 · ownership.direct: Shares held by Forbion Cooperatief. Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 08, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	800	$6.60	$5,278.48	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 13 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,470,633 F13 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.59 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 07, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	11,844	$6.55	$77,530.82	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 12 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,469,833 F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 04, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	5,997	$6.54	$39,241.97	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 11 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,457,989 F11 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.62, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 03, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	5,769	$6.48	$37,396.97	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 10 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,451,992 F10 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.435 to $6.585, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 02, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	10,153	$6.37	$64,696.95	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 9 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,446,223 F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.07 to $6.67, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 01, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	35,279	$6.44	$227,157.95	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 8 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,436,070 F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
September 30, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	341,332	$6.34	$2,163,362.22	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 7 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,400,791 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
September 27, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	3,243	$6.38	$20,688.39	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 6 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,059,459 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
September 27, 2024 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	38,396	$5.94	$228,010.81	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 5 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,056,216 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.31 to $6.30, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
December 29, 2023 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	9,620	$9.09	$87,450.61	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 4 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,017,820 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.65 to $9.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
December 29, 2023 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	400	$8.30	$3,320.00	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 3 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,008,200 F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
December 28, 2023 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	5,050	$7.69	$38,826.93	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 2 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,007,800 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.48 to $8.19, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
December 27, 2023 Filed Oct 18, 2024 16:15 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	PurchaseCommon Shares	2,750	$7.17	$19,711.45	Disclosure SEC source: 0000950170-24-115607 · ownership.xml · nonDerivative · entry 1 Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,002,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.10 to $7.37, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.direct: Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Cooperatief"). Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. Read SEC document
October 31, 2023 Filed Nov 2, 2023 17:29 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	OtherWarrant (Right to Buy) · Derivative	950,153	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0000950103-23-015956 · dp202278_4-forbion.xml · derivative · entry 5 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,736,406 Underlying: Class A Common Stock · 950,153 shares Expires not disclosed F2 · kind: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "Convertible Bridge Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F2 · price: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "Convertible Bridge Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F9 · derivative.exercise_date: Each warrant entitles the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the combination between the Issuer and Forbion European Acquisition Corp. The warrants expire five years following the such combination. F9 · derivative.expiration_date: Each warrant entitles the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the combination between the Issuer and Forbion European Acquisition Corp. The warrants expire five years following the such combination. F3 · ownership.nature: Reflects shares and warrants held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. F5 · ownership.nature: Forbion Cooperatief wholly owns Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F6 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, Sponsor, over the shares held by Sponsor. F7 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the shares reported herein, no member of Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F8 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2023 Filed Nov 2, 2023 17:29 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	OtherWarrant (Right to Buy) · Derivative	54,634	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0000950103-23-015956 · dp202278_4-forbion.xml · derivative · entry 4 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 786,253 Underlying: Class A Common Stock · 54,634 shares Expires not disclosed F1 · kind: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "PIPE Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F1 · price: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "PIPE Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F9 · derivative.exercise_date: Each warrant entitles the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the combination between the Issuer and Forbion European Acquisition Corp. The warrants expire five years following the such combination. F9 · derivative.expiration_date: Each warrant entitles the holder thereof to purchase one share of Class A Common Stock at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the combination between the Issuer and Forbion European Acquisition Corp. The warrants expire five years following the such combination. F3 · ownership.nature: Reflects shares and warrants held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. F5 · ownership.nature: Forbion Cooperatief wholly owns Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F6 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, Sponsor, over the shares held by Sponsor. F7 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the shares reported herein, no member of Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F8 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2023 Filed Nov 2, 2023 17:29 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	OtherClass A Common Stock	2,262,351	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015956 · dp202278_4-forbion.xml · nonDerivative · entry 2 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 3,765,932 F2 · kind: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "Convertible Bridge Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F2 · price: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "Convertible Bridge Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F3 · ownership.nature: Reflects shares and warrants held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. F5 · ownership.nature: Forbion Cooperatief wholly owns Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F6 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, Sponsor, over the shares held by Sponsor. F7 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the shares reported herein, no member of Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F8 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 31, 2023 Filed Nov 2, 2023 17:29 UTC	enGene Therapeutics Inc. ENGN · Entity 6638	OtherClass A Common Stock	130,085	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015956 · dp202278_4-forbion.xml · nonDerivative · entry 1 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,503,581 F1 · kind: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "PIPE Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F1 · price: Reflects shares of Class A Common Stock and warrants acquired pursuant to the consummation of the "PIPE Financing", as described in more detail in the Issuer's registration statement on Form S-4 filed with the Securities and Exchange Commission on September 26, 2023. F3 · ownership.nature: Reflects shares and warrants held by Forbion Growth Sponsor FEAC I B.V. ("Sponsor"). Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra ("Sponsor Board"). All voting and dispositive decisions with respect to the shares held by Sponsor are made by a majority vote of Sponsor Board. F5 · ownership.nature: Forbion Cooperatief wholly owns Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F6 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, Sponsor, over the shares held by Sponsor. F7 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the shares reported herein, no member of Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F8 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 30, 2023 Filed Oct 31, 2023 19:05 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	Disposition to issuerWarrant (Right to Buy) · Derivative	666,666	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0000950103-23-015723 · dp202116_4-forbion3.xml · derivative · entry 4 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 666,666 shares Expires not disclosed F9 · kind: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F9 · price: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F8 · derivative.exercise_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F8 · derivative.expiration_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F3 · ownership.nature: Reflects shares held by Forbion Growth Opportunities Fund I cooperatief U.A. ("Forbion Cooperatief"). F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 30, 2023 Filed Oct 31, 2023 19:05 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	Disposition to issuerWarrant (Right to Buy) · Derivative	731,619	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0000950103-23-015723 · dp202116_4-forbion3.xml · derivative · entry 3 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 731,619 shares Expires not disclosed F9 · kind: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F9 · price: On October 31, 2023, in connection with the Issuer's initial business combination, each warrant was assumed by New enGene and converted into a warrant entitling the holder thereof to purchase one New enGene Share at a price of $11.50 per share, as described in more detail in the Business Combination Agreement F8 · derivative.exercise_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F8 · derivative.expiration_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F2 · ownership.nature: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 30, 2023 Filed Oct 31, 2023 19:05 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	Disposition to issuerClass A Ordinary Shares	2,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015723 · dp202116_4-forbion3.xml · nonDerivative · entry 2 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · price: On October 31, 2023, in connection with the consummation of the Issuer's initial business combination, Class A Ordinary Shares were exchanged, on a one-for-one basis, for Class A common shares ("New enGene Shares") of enGene Holdings, Inc., a corporation incorporated under the laws of Canada ("New enGene"), which will be the parent company of the combined operating business following the consummation of initial business combination, as described in more detail in that certain Business Combination Agreement between the Issuer, enGene Inc. and enGene Holdings Inc., dated May 16, 2023 (the "Business Combination Agreement"). F3 · ownership.nature: Reflects shares held by Forbion Growth Opportunities Fund I cooperatief U.A. ("Forbion Cooperatief"). F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 30, 2023 Filed Oct 31, 2023 19:05 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	Disposition to issuerClass A Ordinary Shares	1,373,496	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015723 · dp202116_4-forbion3.xml · nonDerivative · entry 1 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · price: On October 31, 2023, in connection with the consummation of the Issuer's initial business combination, Class A Ordinary Shares were exchanged, on a one-for-one basis, for Class A common shares ("New enGene Shares") of enGene Holdings, Inc., a corporation incorporated under the laws of Canada ("New enGene"), which will be the parent company of the combined operating business following the consummation of initial business combination, as described in more detail in that certain Business Combination Agreement between the Issuer, enGene Inc. and enGene Holdings Inc., dated May 16, 2023 (the "Business Combination Agreement"). F2 · ownership.nature: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 27, 2023 Filed Oct 31, 2023 18:59 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	GrantWarrant (Right to Buy) · Derivative	1,000,000	$1.50 Strike: $11.50	$1,500,000.00	Disclosure SEC source: 0000950103-23-015722 · dp202115_4-forbion2.xml · derivative · entry 4 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 731,619 Underlying: Class A Ordinary Shares · 1,000,000 shares Expires not disclosed F9 · derivative.exercise_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F9 · derivative.expiration_date: Each warrant entitles the holder thereof to purchase one Class A Ordinary Share at a price of $11.50 per share, and first becomes exercisable 30 days after the consummation of the Issuer's initial business combination. The warrants expire five years following the Issuer's initial business combination. The warrants also expire if the Issuer fails to consummate the initial business combination within 24 months from the Issuer's initial public offering. F8 · balance_after: Reflects the cancellation, for no consideration, of 1,789,004 Class B Ordinary Shares and 5,463,381 warrants held by the Sponsor, in each case that is exempt pursuant to Rule 16b-6(d). F2 · ownership.nature: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 27, 2023 Filed Oct 31, 2023 18:59 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	ConversionClass B Ordinary Shares · Derivative	1,373,496	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015722 · dp202115_4-forbion2.xml · derivative · entry 3 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 1,373,496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the conversion of Class B Ordinary Shares into a Class A Ordinary Share in accordance with its terms. F1 · price: Reflects the conversion of Class B Ordinary Shares into a Class A Ordinary Share in accordance with its terms. F1 · derivative.exercise_date: Reflects the conversion of Class B Ordinary Shares into a Class A Ordinary Share in accordance with its terms. F1 · derivative.expiration_date: Reflects the conversion of Class B Ordinary Shares into a Class A Ordinary Share in accordance with its terms. F8 · balance_after: Reflects the cancellation, for no consideration, of 1,789,004 Class B Ordinary Shares and 5,463,381 warrants held by the Sponsor, in each case that is exempt pursuant to Rule 16b-6(d). F2 · ownership.nature: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document
October 27, 2023 Filed Oct 31, 2023 18:59 UTC	Forbion European Acquisition Corp. FRBNU · Entity 108709	ConversionClass A Ordinary Shares	1,373,496	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-015722 · dp202115_4-forbion2.xml · nonDerivative · entry 1 Forbion Growth Sponsor FEAC I B.V. · CIK 0001897943 · Director · 10% owner Forbion Growth Opportunities Fund I Cooperatief U.A. · CIK 0001911047 · Director · 10% owner Forbion Growth Management B.V. · CIK 0001918318 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,373,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reflects the conversion of Class B Ordinary Shares into a Class A Ordinary Share in accordance with its terms. F2 · ownership.nature: Reflects shares held by Forbion Growth Sponsor FEAC I B.V. (the "Sponsor"). The Sponsor is controlled by a four-person Board of Managers comprised of J.M Bos, C. Lesser, S. Slootweg and W.S.J. Joustra (the "Sponsor Board"). All voting and dispositive decisions with respect to the shares held by the Sponsor are made by a majority vote of the Sponsor Board. F4 · ownership.nature: Forbion Cooperatief wholly owns the Sponsor. Forbion Growth Management B.V. is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. F5 · ownership.nature: Sponsor and Forbion Cooperatief may be deemed to have shared voting and investment power over the shares held by the Sponsor. Forbion Management may be deemed to share voting and investment power (i) with Forbion Cooperatief over the shares held by Forbion Cooperatief and (ii) with Forbion Cooperatief and, indirectly, the Sponsor, over the shares held by the Sponsor. F6 · ownership.nature: Under the so-called "rule of three," if voting and dispositive decisions regarding an entity's securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, none of the individuals is deemed a beneficial owner of the entity's securities. Accordingly, because none of the members of the Sponsor Board or the Management Investment Committee has individual voting or investment control over any of the Class A Ordinary Shares or Class B Ordinary Shares reported herein, no member of the Sponsor Board or the Management Investment Committee is deemed to have or share beneficial ownership of such shares. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.